No Data
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Changchun High-Tech Industry (Group) Co., Ltd.'s (SZSE:000661) Shares Not Telling The Full Story
Changchun High-Tech Industry's Subsidiary Gets Nod to Trial Solid Tumor Drug
Changchun High-Tech Industries (000661.SZ) has repurchased a total of 0.67% of its shares, spending approximately 0.3 billion yuan.
Changchun High-Tech Industries (000661.SZ) announced that as of March 31, 2025, through centralized competitive trading...
Changchun High-Tech Industry's Subsidiary Gets Nod to Trial Rheumatoid Arthritis Drug in US
Changchun High-Tech Industries (000661.SZ): The clinical trial application for the new drug GenSci120 injection from the subsidiary has received implied approval from the FDA in the USA.
Gelonghui March 20th丨Changchun High-Tech Industries (000661.SZ) announced that recently, Changchun High-Tech Industries (Group) Co., Ltd.'s holding subsidiary, Changchun JinSai Pharmaceutical Co., Ltd. (referred to as "JinSai Pharmaceutical") received notification from the USA Food and Drug Administration (referred to as "USA FDA") that JinSai Pharmaceutical's GenSci120 injection new drug clinical trial application has obtained implied approval. GenSci120 injection is a humanized PD-1 monoclonal antibody developed by JinSai Pharmaceutical, which activates the PD-1 inhibitory signaling pathway and ADCC effects by binding to PD-1, thus inhibiting.
102884128 : getting disappointed with this counter. every day drop.